Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.60 |
| ▸ | QPCT | Q16769 | 3/20 | 0.48 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638693 | 0.82 | QPCT (0.51) | ADORA2AQPCTQPCTLALOX5APFEN1 | |
| SCHEMBL16473301 | 0.82 | QPCT (0.51) | ADORA2AQPCTQPCTLTDO2ALOX5AP | |
| SCHEMBL15639302 | 0.79 | QPCT (0.48) | ADORA2AQPCTQPCTLALOX5APFEN1 | |
| SCHEMBL15638995 | 0.78 | QPCT (0.47) | ADORA2AQPCTQPCTLALOX5APFEN1 | |
| SCHEMBL15637546 | 0.78 | ADORA2A (0.57) | ADORA2ACLK4TDO2KCNN4KCNA5 | |
| SCHEMBL22246315 | 0.76 | ADORA2A (0.69) | ADORA2AQPCTQPCTLTDO2PRKCI | |
| SCHEMBL15637746 | 0.76 | ADORA2A (0.59) | ADORA2ACLK4 | |
| SCHEMBL30117520 | 0.76 | RAF1 (0.44) | ADORA2ACLK4TDO2IDO1KCNN4 | |
| SCHEMBL15639677 | 0.76 | RAF1 (0.44) | ADORA2ACLK4TDO2IDO1KCNN4 | |
| SCHEMBL15640015 | 0.75 | ALOX5AP (0.51) | ADORA2AQPCTQPCTLALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | ADORA2A 1392/4885QPCT 2031/4885QPCTL 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.